CONDUIT PHARMACEUTICALS INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q4 2021 to Q2 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Conduit Pharmaceuticals Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q4 2021 to Q2 2023.
- Conduit Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was -$131K, a 49.1% decline year-over-year.
- Conduit Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending June 30, 2023 was $1.14M.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)